RU2005135739A - Способ регулирования активации лимфоцита (варианты) - Google Patents
Способ регулирования активации лимфоцита (варианты) Download PDFInfo
- Publication number
- RU2005135739A RU2005135739A RU2005135739/13A RU2005135739A RU2005135739A RU 2005135739 A RU2005135739 A RU 2005135739A RU 2005135739/13 A RU2005135739/13 A RU 2005135739/13A RU 2005135739 A RU2005135739 A RU 2005135739A RU 2005135739 A RU2005135739 A RU 2005135739A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- soluble form
- lymphocyte
- amino acid
- activation
- Prior art date
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims 6
- 230000004913 activation Effects 0.000 title claims 5
- 230000001105 regulatory effect Effects 0.000 title claims 3
- 229940123944 B7-H3 antagonist Drugs 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960004222 factor ix Drugs 0.000 claims 1
- 229960000301 factor viii Drugs 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46334203P | 2003-04-17 | 2003-04-17 | |
| US60/463,342 | 2003-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005135739A true RU2005135739A (ru) | 2006-03-20 |
Family
ID=33310770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005135739/13A RU2005135739A (ru) | 2003-04-17 | 2004-04-16 | Способ регулирования активации лимфоцита (варианты) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20050002935A1 (enExample) |
| EP (1) | EP1620119A2 (enExample) |
| JP (2) | JP2006523711A (enExample) |
| KR (1) | KR20060017496A (enExample) |
| CN (1) | CN1809370A (enExample) |
| AU (1) | AU2004231748A1 (enExample) |
| BR (1) | BRPI0409476A (enExample) |
| CA (1) | CA2521847A1 (enExample) |
| CO (1) | CO5700783A2 (enExample) |
| MX (1) | MXPA05011050A (enExample) |
| NO (1) | NO20054790L (enExample) |
| RU (1) | RU2005135739A (enExample) |
| WO (1) | WO2004093894A2 (enExample) |
| ZA (1) | ZA200508367B (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7960348B2 (en) | 2005-12-22 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8361968B2 (en) | 2002-12-26 | 2013-01-29 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8765909B2 (en) | 2006-10-25 | 2014-07-01 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8778871B2 (en) | 2004-06-25 | 2014-07-15 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001094413A2 (en) | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| CA2668800A1 (en) * | 2006-11-08 | 2008-06-05 | Macrogenics West, Inc. | Tes7 and antibodies that bind thereto |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| EP2703486B1 (en) * | 2011-04-25 | 2018-03-07 | Daiichi Sankyo Company, Limited | Anti-b7-h3 antibody |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| US10100115B2 (en) | 2014-02-14 | 2018-10-16 | Macrogenics, Inc. | Methods for the treatment of vascularizing cancers |
| BR112018006817A2 (pt) | 2015-10-08 | 2018-10-23 | Macrogenics Inc | método de tratamento do câncer |
| EP3442574A4 (en) | 2016-04-15 | 2019-12-11 | MacroGenics, Inc. | Novel B7-H3 binding MOLECULES, ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE THEREOF |
| BR112019019111A2 (pt) * | 2017-03-31 | 2020-05-05 | Jiangsu Hengrui Medicine Co | anticorpo de b7-h3, seu fragmento de ligação ao antígeno e seu uso médico |
| CN109097366A (zh) * | 2017-06-21 | 2018-12-28 | 黄海东 | 突变的人2Ig-B7-H3蛋白编码基因、重组载体、其药物组合物及其应用 |
| US12312406B2 (en) | 2018-11-09 | 2025-05-27 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Anti-B7-H3 antibody, preparation method therefor, conjugate and application thereof |
| SG11202106952UA (en) * | 2018-12-24 | 2021-08-30 | Haidong Huang | Recombinant human 2ig-b7-h3 protein coding gene, recombinant vector, host cell comprising the same, pharmaceutical composition and use thereof |
| CN118878681A (zh) * | 2019-07-18 | 2024-11-01 | 泰州复旦张江药业有限公司 | 一种抗b7-h3抗体及其制备方法、其偶联物和应用 |
| CN111454357B (zh) * | 2019-08-14 | 2022-03-15 | 康诺亚生物医药科技（成都）有限公司 | 一种含有抗体的肿瘤治疗剂的开发和应用 |
| CN111088227A (zh) * | 2019-12-31 | 2020-05-01 | 广州航华生物医药科技有限公司 | 一种细胞分离培养液和t细胞分离培养的方法 |
| CN120093941A (zh) | 2021-02-09 | 2025-06-06 | 苏州宜联生物医药有限公司 | 生物活性物偶联物及其制备方法和用途 |
| CN113144181B (zh) * | 2021-04-20 | 2022-07-19 | 徐州医科大学 | 一种靶向b7h3的dna疫苗、制备方法及应用 |
| US20250144229A1 (en) | 2022-02-16 | 2025-05-08 | Medlink Therapeutics (Suzhou) Co., Ltd. | Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof |
| US20250325688A1 (en) | 2022-05-18 | 2025-10-23 | Medilink Therapeutics (Suzhou) Co., Ltd. | Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof |
| CN120898001A (zh) * | 2023-01-10 | 2025-11-04 | 上海仁又生基因技术有限公司 | 重组人2Ig-B7-H3蛋白编码基因、重组载体、宿主细胞、药物组合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001094413A2 (en) * | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| AU2001283507A1 (en) * | 2000-07-27 | 2002-02-13 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
| AU2002347761A1 (en) * | 2001-08-02 | 2003-02-24 | Eli Lilly And Company | Novel polypeptide analogs and fusions and their methods of use |
-
2004
- 2004-04-15 US US10/824,481 patent/US20050002935A1/en not_active Abandoned
- 2004-04-16 WO PCT/US2004/011767 patent/WO2004093894A2/en not_active Ceased
- 2004-04-16 MX MXPA05011050A patent/MXPA05011050A/es not_active Application Discontinuation
- 2004-04-16 JP JP2006510118A patent/JP2006523711A/ja not_active Withdrawn
- 2004-04-16 CA CA002521847A patent/CA2521847A1/en not_active Abandoned
- 2004-04-16 BR BRPI0409476-0A patent/BRPI0409476A/pt not_active IP Right Cessation
- 2004-04-16 KR KR1020057019786A patent/KR20060017496A/ko not_active Withdrawn
- 2004-04-16 AU AU2004231748A patent/AU2004231748A1/en not_active Abandoned
- 2004-04-16 RU RU2005135739/13A patent/RU2005135739A/ru not_active Application Discontinuation
- 2004-04-16 CN CNA2004800170492A patent/CN1809370A/zh not_active Withdrawn
- 2004-04-16 EP EP04750222A patent/EP1620119A2/en not_active Withdrawn
-
2005
- 2005-10-14 ZA ZA200508367A patent/ZA200508367B/en unknown
- 2005-10-18 NO NO20054790A patent/NO20054790L/no not_active Application Discontinuation
- 2005-11-17 CO CO05116756A patent/CO5700783A2/es not_active Application Discontinuation
-
2007
- 2007-03-30 JP JP2007095108A patent/JP2007191489A/ja not_active Withdrawn
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8361968B2 (en) | 2002-12-26 | 2013-01-29 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8778871B2 (en) | 2004-06-25 | 2014-07-15 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US7960348B2 (en) | 2005-12-22 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8765909B2 (en) | 2006-10-25 | 2014-07-01 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20054790L (no) | 2005-11-16 |
| CN1809370A (zh) | 2006-07-26 |
| ZA200508367B (en) | 2007-04-25 |
| JP2006523711A (ja) | 2006-10-19 |
| WO2004093894A2 (en) | 2004-11-04 |
| WO2004093894A3 (en) | 2005-03-24 |
| JP2007191489A (ja) | 2007-08-02 |
| MXPA05011050A (es) | 2006-03-17 |
| CO5700783A2 (es) | 2006-11-30 |
| KR20060017496A (ko) | 2006-02-23 |
| NO20054790D0 (no) | 2005-10-18 |
| BRPI0409476A (pt) | 2006-05-02 |
| AU2004231748A1 (en) | 2004-11-04 |
| WO2004093894A8 (en) | 2005-05-19 |
| EP1620119A2 (en) | 2006-02-01 |
| US20050002935A1 (en) | 2005-01-06 |
| CA2521847A1 (en) | 2004-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005135739A (ru) | Способ регулирования активации лимфоцита (варианты) | |
| US12072334B2 (en) | Corneal endothelial cell marker | |
| CA2836855C (en) | Polypeptides and uses thereof for treatment of autoimmune disorders and infection | |
| CN103608456B (zh) | 适体在自体免疫疾病的疗法和/或诊断中的用途 | |
| JP2006523711A5 (enExample) | ||
| JP4776228B2 (ja) | Ｔヘルパー（ｔｈ）細胞の発生および機能を調節するための方法および組成物 | |
| EA015351B1 (ru) | Антагонисты il-17a и il-17f и способы их применения | |
| JP6653775B1 (ja) | キメラ抗原受容体、核酸、キメラ抗原受容体発現プラスミド、キメラ抗原受容体発現細胞、その使用及びがん治療用の医薬組成物 | |
| EA202192024A1 (ru) | Рецепторы, обеспечивающие прицельную костимуляцию, для адоптивной клеточной терапии | |
| PT1897548E (pt) | Regulação de células t | |
| JP7650795B2 (ja) | Ｂ細胞を活性化するｃｄ７３抗体 | |
| JP2022512922A (ja) | キメラ抗原受容体記憶様（ｃａｒｍｌ）ｎｋ細胞ならびにその産生および使用方法 | |
| JP2003523735A5 (enExample) | ||
| US20210032334A1 (en) | Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents | |
| CN110051836B (zh) | 使用膜stim1筛选化合物的方法 | |
| JPWO2019236593A5 (enExample) | ||
| Ross | G Protein-Coupled Receptors: Structural Basis of Selective Signaling | |
| Desai et al. | Cholecystokinin type 1 receptor | |
| RU2023134125A (ru) | Белки управления, навигации и контроля и способ их получения и применения | |
| CA2566041A1 (en) | T-type calcium channel splice variant compositions and methods | |
| WO1997004093A1 (fr) | Sequences nucleotidiques et peptidiques pour le traitement de la myasthenie | |
| ES2172359B1 (es) | Peptido capaz de inducir anticuerpos contra la subunidad ka1 de los receptores de kainato de mamiferos, anticuerpo policlonal contra dicha subunidad ka1 y un procedimiento para su obtencion. | |
| HK1191033A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20070417 |